, /PRNewswire/ -- The global inflammatory bowel disease market size is estimated to grow by from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.48% during the forecast period.
Increasing incidence of ibd worldwide is driving market growth, with a trend towards new launches of ibd therapeutics. However, high cost of ibd therapeutics poses a challenge. Key market players include Abbott Laboratories, AbbVie Inc.
, AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Baxter International Inc.
, Bayer AG, Biocon Ltd., Eli Lilly and Co., F.
Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd.
, Merck and Co. Inc., Novartis AG, Pfizer Inc.
, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
. Get a detailed analysis on regions, market segments, customer landscape, and companies - The global Inflammatory Bowel Disease (IBD) market is experiencing significant growth due to the introduction of new therapeutics. Pharmaceutical and biopharmaceutical companies are increasing their research and development (R&D) spending, leading to new product launches.
For instance, Lupin launched Mirabegron Extended-Release Tablets in the US in , and HUMIRA (Adalimumab), a TNF blocker, received approval for pediatric use in . These advancements are expected to continue driving market expansion during the forecast period. The Inflammatory Bowel Disease market is experien.
